Immunotech Biopharm Ltd

Equities

6978

KYG4721A1004

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:05 31/05/2024 pm IST			5-day change	1st Jan Change
3.11 ^HKD	+11.47%		+1.63%	-37.80%

29/03	Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023	MT
28/03	Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Immunotech Biopharm Ltd Announces Change of Senior Management

April 13, 2021 at 08:18 pm IST

The board of directors of Immunotech Biopharm Ltd. announced that on 13 April 2021 (after trading hours), Dr. Kim Ho-un has tendered his resignation as the co-chief technology officer ("CTO") of the Group and Dr. Lee Hyun-soo has been appointed as the new co-CTO on 13 April 2021.

Latest news about Immunotech Biopharm Ltd

Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023	29/03	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Immunotech Biopharm Obtains Clinical Trial Nod in China for Leukemia Drug	19/02	MT
Immunotech Biopharm Receives an Approval of the Investigational New Drug Application for Phase I Clinical Trial from the Centre for Drug Evaluation of the National Medical Products Administration for the aT19 Injection	19/02	CI
Immunotech Biopharm Ltd Announces First Patient Enrolled in the Phase II Clinical Trialfor Car-T-19 Injection	03/01	CI
Chinese Drug Regulator Accepts Immunotech Biopharm's Application for AT19 Injection	27/11	MT
Immunotech Biopharm Enrolls First Patient in Clinical Trial of Lymphoma Drug	07/11	MT
Immunotech Biopharm Ltd Completes the First Patient Enrolment for its Phase I Clinical Trial for the Denocabtagene Ciloleucel Injection	07/11	CI
China Grants Breakthrough Therapy Designation to Immunotech's Liver Cancer Medication; Shares Fall 5%	06/23/06	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	27/23/27	CI
Immunotech Biopharm Ltd Announces Board Changes	27/23/27	CI
Immunotech Biopharm Ltd Announces Director Changes	26/23/26	CI
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Immunotech Biopharm Obtains China Clinical Trial Approval for Lymphoma Treatment	22/23/22	MT
Immunotech Biopharm Ltd Obtains the Clinical Approval for the Denocabtagene Ciloleucel Injection from the National Medical Products Administration	21/23/21	CI
Immunotech Biopharm Extends Completion Date of Convertible Bond Sale	26/23/26	MT
Immunotech Biopharm’s New Drug Application for Lymphoma Injection Accepted by Chinese Regulator	29/22/29	MT
Immunotech Biopharm Ltd. Receives Acceptance Notice for the Investigational New Drug Application for the Denocabtagene Ciloleucel Injection	28/22/28	CI
Immunotech Biopharm Shareholders to Meet on Convertible Bond Issuance	16/22/16	MT
Immunotech Biopharm Ltd announced that it expects to receive CNY 300 million in funding from Tianjin Tasly Pharmaceutical Co., Ltd., Investment Arm	28/22/28	CI
Immunotech Biopharm Sees $19.6 Million H1 Loss	26/22/26	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	26/22/26	CI
Immunotech Biopharm, NKY Medical Form Tumor Diagnostics JV in Shanghai	03/22/03	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	25/22/25	CI
Immunotech Biopharm Seeks Clinical Trial Nod in China for B-Cell Lymphoma Treatment	04/22/04	MT

Chart Immunotech Biopharm Ltd

Duration

Period

More charts

Company Profile

Immunotech Biopharm Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of immune cell products for treatments of cancers. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. It also provides cell cryopreservation services. The Company mainly conducts its businesses in the domestic market.

Sector

Biotechnology & Medical Research

Calendar

20/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNOTECH BIOPHARM LTD	-37.80%	205M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs